doi:10.1038/leu.2014.184engFernández-Rodríguez, CBellosillo, BGarcía-García, MSánchez-González, BGimeno, EVela, M CSerrano, SBesses, CSalar, AMYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphomaART-2014-129720Diffuse large B-cell lymphoma (DLBCL) encompasses an aggressive and heterogeneous group of malignancies. Gene expression profiling (GEP) unraveled two main subtypes based on their putative cell of origin named germinal center B-cell-like (GCB) and activated B-cell-like (ABC), with specific genetic alterations and different clinical outcome. Recent studies have reported several somatic mutations in the myeloid differentiation primary response gene 88 (MYD88) affecting B-cell lymphomas. Among them, the leucine to proline exchange at position 265 (L265P) is the most recurrent and biologically potent MYD88 variation, being found in about 30% of ABC-DLBCL but uncommon in GCB-DLBCL. Here, we have investigated the occurrence of MYD88 L265P mutation in adult patients with DLBCL and its relation to clinical and biological characteristics, including patients’ outcome.2014http://zaguan.unizar.es/record/14784110.1038/leu.2014.184http://zaguan.unizar.es/record/147841oai:zaguan.unizar.es:147841Leukemia 28, 10 (2014), 2104-2106All rights reservedhttp://www.europeana.eu/rights/rr-f/info:eu-repo/semantics/closedAccess